Institute of Tropical Medicine Antwerp
Foundation of Public Utility

Efficacy of dihydroartemisinin/piperaquine and artesunate monotherapy for the treatment of uncomplicated Plasmodium falciparum malaria in Central Vietnam

DSpace/Manakin Repository

Show simple item record Rovira-Vallbona, E. en_US Van Hong, N. en_US Kattenberg, J. H. en_US Huan, R. M. en_US Hien, N. T. T. en_US Ngoc, N. T. H. en_US Guetens, P. en_US Hieu, N. L. en_US Mai, T. T. en_US Duong, N. T. T. en_US Duong, T. T. en_US Phuc, B. Q. en_US Xa, N. X. en_US Erhart, A. en_US Rosanas-Urgell, A. en_US 2020-08-25T09:38:09Z 2020-08-25T09:38:09Z 2020 en_US
dc.identifier.issn 0305-7453 en_US
dc.identifier.doi en_US
dc.identifier.other ITG-B1A; ITG-B3A; ITG-B7A; ITG-BLA; DBM; U-MALAR; JIF; DOI; CPDF; PMC; Abstract; ITMPUB; DSPACE68 en_US
dc.description.abstract BACKGROUND: Artemisinin-based combination therapies (ACTs) have significantly contributed to reduce Plasmodium falciparum malaria burden in Vietnam, but their efficacy is challenged by treatment failure of dihydroartemisinin/piperaquine ACT in Southern provinces. OBJECTIVES: To assess the efficacy of dihydroartemisinin/piperaquine for uncomplicated P. falciparum malaria in Gia Lai, Central Vietnam, and determine parasite resistance to artemisinin ( identifier NCT02604966). METHODS: Sixty patients received either dihydroartemisinin/piperaquine (4 mg/kg/day, 3 days; n = 33) or artesunate monotherapy (4 mg/kg/day, 3 days; n = 27) followed by dihydroartemisinin/piperaquine (AS + DHA/PPQ). Clinical phenotypes were determined during a 42 day follow-up and analysed together with ex vivo susceptibility to antimalarials and molecular markers of drug resistance. RESULTS: Day 3 positivity rate was significantly higher in the AS + DHA/PPQ arm compared with dihydroartemisinin/piperaquine (70.4% versus 39.4%, P = 0.016). Parasite clearance time was 95.2 h (AS + DHA/PPQ) versus 71.9 h (dihydroartemisinin/piperaquine, P = 0.063) and parasite clearance half-life was 7.4 h (AS + DHA/PPQ) versus 7.0 h (dihydroartemisinin/piperaquine, P = 0.140). Adequate clinical and parasitological response at Day 42 was 100% in both arms. By RT-qPCR, 36% (19/53) patients remained positive until Day 7. No recurrences were detected. kelch13 artemisinin resistance mutations were found in 87% (39/45) of isolates and 50% (20/40) were KEL1/C580Y. The piperaquine resistance marker plasmepsin-2 was duplicated in 10.4% (5/48). Isolates from Day 3-positive patients (n = 18) had higher ex vivo survival rates to artemisinin compounds (P < 0.048) and prevalence of kelch13 mutations (P = 0.005) than Day 3-negative patients (n = 5). The WHO definition of artemisinin resistance was fulfilled in 60% (24/40) of cases. CONCLUSIONS: Although dihydroartemisinin/piperaquine remained effective to treat P. falciparum, the high Day 3 positivity rate and prevalence of KEL1 strains calls for continuous monitoring of dihydroartemisinin/piperaquine efficacy in Central Vietnam. en_US
dc.language English en_US
dc.relation.uri en_US
dc.subject Malaria en_US
dc.subject Protozoal diseases en_US
dc.subject Treatment regimen en_US
dc.subject Dihydroartemisinin-piperaquine en_US
dc.subject Artesunate en_US
dc.subject Vietnam en_US
dc.subject Asia-Southeast en_US
dc.title Efficacy of dihydroartemisinin/piperaquine and artesunate monotherapy for the treatment of uncomplicated Plasmodium falciparum malaria in Central Vietnam en_US
dc.type Article en_US
dc.citation.issue 8 en_US
dc.citation.jtitle Journal of Antimicrobial Chemotherapy en_US
dc.citation.volume 75 en_US
dc.citation.pages 2272-2281 en_US
dc.citation.abbreviation J Antimicrob Chemother en_US

Files in this item

This item appears in the following Collection(s)

Show simple item record